In terms of safety outcomes, SGLT2 inhibitors significantly reduced the risk of AKI by 22%, increased the risk of UTIs by 8%, and there were no significant differences observed in the risks of adverse events and hypoglycemia in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.